Author:
Tsimikas Sotirios,Fazio Sergio,Ferdinand Keith C.,Ginsberg Henry N.,Koschinsky Marlys L.,Marcovina Santica M.,Moriarty Patrick M.,Rader Daniel J.,Remaley Alan T.,Reyes-Soffer Gissette,Santos Raul D.,Thanassoulis George,Witztum Joseph L.,Danthi Simhan,Olive Michelle,Liu Lijuan
Subject
Cardiology and Cardiovascular Medicine
Reference77 articles.
1. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies;Tsimikas;J Am Coll Cardiol,2017
2. Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients;Moriarty;Arterioscler Thromb Vasc Biol,2017
3. PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis;Langsted;J Clin Endocrinol Metab,2016
4. Carriers of the PCSK9 R46L variant are characterized by an antiatherogenic lipoprotein profile assessed by nuclear magnetic resonance spectroscopy-brief report;Verbeek;Arterioscler Thromb Vasc Biol,2017
5. 2016 ESC/EAS guidelines for the management of dyslipidaemias;Catapano;Eur Heart J,2016
Cited by
364 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献